Bachem Holding AG

SWX:BANB Stock Report

Market Cap: CHF 6.7b

Bachem Holding Valuation

Is BANB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BANB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BANB (CHF89.75) is trading above our estimate of fair value (CHF22.15)

Significantly Below Fair Value: BANB is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BANB?

Other financial metrics that can be useful for relative valuation.

BANB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.1x
Enterprise Value/EBITDA39.4x
PEG Ratio3.7x

Price to Earnings Ratio vs Peers

How does BANB's PE Ratio compare to its peers?

The above table shows the PE ratio for BANB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average47.9x
SFZN Siegfried Holding
37.2x14.7%CHF 4.2b
TECN Tecan Group
30.9x9.5%CHF 4.1b
SKAN SKAN Group
68.2x19.4%CHF 1.8b
LONN Lonza Group
55.5x20.6%CHF 36.3b
BANB Bachem Holding
60.2x16.2%CHF 6.7b

Price-To-Earnings vs Peers: BANB is expensive based on its Price-To-Earnings Ratio (60.2x) compared to the peer average (47.9x).

Price to Earnings Ratio vs Industry

How does BANB's PE Ratio compare vs other companies in the European Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.6%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a19.6%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: BANB is expensive based on its Price-To-Earnings Ratio (60.2x) compared to the European Life Sciences industry average (37.8x).

Price to Earnings Ratio vs Fair Ratio

What is BANB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BANB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio60.2x
Fair PE Ratio26.2x

Price-To-Earnings vs Fair Ratio: BANB is expensive based on its Price-To-Earnings Ratio (60.2x) compared to the estimated Fair Price-To-Earnings Ratio (26.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BANB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 89.75
CHF 75.67
-15.7%
22.1%CHF 100.00CHF 52.00n/a6
Jul ’25CHF 82.75
CHF 75.67
-8.6%
22.1%CHF 100.00CHF 52.00n/a6
Jun ’25CHF 80.85
CHF 70.80
-12.4%
19.6%CHF 85.00CHF 52.00n/a5
May ’25CHF 80.15
CHF 70.80
-11.7%
19.6%CHF 85.00CHF 52.00n/a5
Apr ’25CHF 86.40
CHF 70.80
-18.1%
19.6%CHF 85.00CHF 52.00n/a5
Mar ’25CHF 70.15
CHF 71.17
+1.4%
17.6%CHF 85.00CHF 52.00n/a6
Feb ’25CHF 58.10
CHF 71.17
+22.5%
17.6%CHF 85.00CHF 52.00n/a6
Jan ’25CHF 65.00
CHF 73.17
+12.6%
13.7%CHF 85.00CHF 56.00n/a6
Dec ’24CHF 65.00
CHF 75.33
+15.9%
9.3%CHF 85.00CHF 64.00n/a6
Nov ’24CHF 65.95
CHF 75.33
+14.2%
9.3%CHF 85.00CHF 64.00n/a6
Oct ’24CHF 68.00
CHF 77.00
+13.2%
12.7%CHF 95.00CHF 64.00n/a6
Sep ’24CHF 82.05
CHF 80.00
-2.5%
14.1%CHF 97.00CHF 65.00n/a7
Aug ’24CHF 80.35
CHF 82.83
+3.1%
13.6%CHF 97.00CHF 65.00n/a6
Jul ’24CHF 78.00
CHF 87.60
+12.3%
9.3%CHF 97.00CHF 74.00CHF 82.755
Jun ’24CHF 94.00
CHF 91.75
-2.4%
4.8%CHF 97.00CHF 86.00CHF 80.854
May ’24CHF 97.10
CHF 88.20
-9.2%
11.2%CHF 100.00CHF 71.00CHF 80.155
Apr ’24CHF 91.40
CHF 88.20
-3.5%
11.2%CHF 100.00CHF 71.00CHF 86.405
Mar ’24CHF 93.95
CHF 88.20
-6.1%
11.2%CHF 100.00CHF 71.00CHF 70.155
Feb ’24CHF 80.55
CHF 86.80
+7.8%
11.7%CHF 100.00CHF 71.00CHF 58.105
Jan ’24CHF 79.85
CHF 86.80
+8.7%
11.7%CHF 100.00CHF 71.00CHF 65.005
Dec ’23CHF 90.10
CHF 74.40
-17.4%
23.4%CHF 95.00CHF 48.00CHF 65.005
Nov ’23CHF 69.00
CHF 72.83
+5.6%
21.0%CHF 95.00CHF 48.00CHF 65.956
Oct ’23CHF 62.80
CHF 209.50
+233.6%
137.4%CHF 850.00CHF 48.00CHF 68.006
Sep ’23CHF 65.85
CHF 238.20
+261.7%
129.0%CHF 850.00CHF 48.00CHF 82.055
Aug ’23CHF 63.85
CHF 457.40
+616.4%
72.9%CHF 850.00CHF 48.00CHF 80.355
Jul ’23CHF 67.45
CHF 569.65
+744.6%
48.7%CHF 850.00CHF 108.60CHF 78.004

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.